List of Prevymis drug patents
Prevymis is owned by Merck Sharp Dohme.
Prevymis contains Letermovir.
Prevymis has a total of 3 drug patents out of which 0 drug patents have expired.
Prevymis was authorised for market use on 08 November, 2017.
Prevymis is available in solution;intravenous dosage forms.
The generics of Prevymis are possible to be released after 28 February, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(11 months from now) | |
| USRE46791 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(11 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(9 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 8, 2024 |
Drugs and Companies using LETERMOVIR ingredient
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
PREVYMIS family patents
5
European Union
4
United States
3
China
3
Germany
3
Hungary
2
Chile
2
Poland
2
Canada
2
Slovenia
2
Korea, Republic of
2
Ukraine
2
Brazil
2
Hong Kong
2
Morocco
2
Japan
2
Denmark
2
Malaysia
2
Spain
2
Mexico
2
New Zealand
2
Colombia
2
Australia
2
Norway
2
South Africa
2
Portugal
2
Israel
1
ME
1
Philippines
1
Egypt
1
Taiwan
1
Lithuania
1
RS
1
Netherlands
1
Honduras
1
India
1
Croatia
1
Argentina
1
Uruguay
1
EA
1
Ecuador
1
Austria
1
Tunisia
1
Russia
1
Singapore
1
Peru
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic